Anticoagulant Medications for the Prevention and Treatment of Thromboembolism

被引:7
作者
Brien, Lori [1 ,2 ]
机构
[1] Virginia Hosp Ctr, Cardiovasc & Thorac Surg, Arlington, VA 22205 USA
[2] Georgetown Univ, Sch Nursing & Hlth Studies, Adult Gerontol Acute Care Nurse Practitioner Prog, 3700 Reservoir Rd NW, Washington, DC 20057 USA
关键词
anticoagulant; anticoagulation; thromboembolism; thrombosis; INITIAL TREATMENT; WARFARIN; DABIGATRAN; HEPARIN; FONDAPARINUX; MANAGEMENT; THROMBOSIS; GUIDANCE;
D O I
10.4037/aacnacc2019867
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Venous thromboembolism is a preventable medical condition associated with significant morbidity and mortality. It can lead to deep vein thrombosis, pulmonary embolism, and stroke. Thrombi develop when intravascular conditions promote activation of the coagulation system or when there is an imbalance between endogenous anticoagulants and procoagulants. Such conditions include vascular injury, inflammation, venous stasis, and hypercoagulable states. Anticoagulant medications are indicated for the prevention and treatment of venous thromboembolism. They exert their effect on clotting factors to prevent the formation of thrombi or the propagation of an existing clot. Historically, anticoagulants were limited to heparins and vitamin K antagonists. Over the past 15 years, however, several new anticoagulant medications have been introduced. This article describes commonly prescribed and newer anticoagulants available to health care professionals, including their mechanism of action, therapeutic use, unique characteristics, and available reversal agents in the event of life-threatening bleeding.
引用
收藏
页码:126 / 138
页数:13
相关论文
共 29 条
[11]   Dabigatran versus Warfarin in Patients with Mechanical Heart Valves [J].
Eikelboom, John W. ;
Connolly, Stuart J. ;
Brueckmann, Martina ;
Granger, Christopher B. ;
Kappetein, Arie P. ;
Mack, Michael J. ;
Blatchford, Jon ;
Devenny, Kevin ;
Friedman, Jeffrey ;
Guiver, Kelly ;
Harper, Ruth ;
Khder, Yasser ;
Lobmeyer, Maximilian T. ;
Maas, Hugo ;
Voigt, Jens-Uwe ;
Simoons, Maarten L. ;
Van de Werf, Frans .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (13) :1206-1214
[12]   The evolution of anticoagulant therapy [J].
Franchini, Massimo ;
Liumbruno, Giancarlo M. ;
Bonfanti, Carlo ;
Lippi, Giuseppe .
BLOOD TRANSFUSION, 2016, 14 (02) :175-184
[13]  
*GLAXOSMITHKLINE, 2009, AR PRESCR INF
[14]   Heparin-Induced Thrombocytopenia [J].
Greinacher, Andreas .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (03) :252-261
[15]  
Hall JE, 2016, GUYTON HALL TXB MED, P483
[16]  
Hellenbart EL, 2017, VASC HEALTH RISK MAN, V13, P325, DOI 10.2147/VHRM.S121661
[17]   Pharmacokinetic and Pharmacodynamic Drug Interactions With New Oral Anticoagulants: What Do They Mean for Patients With Atrial Fibrillation? [J].
Hellwig, Thaddaus ;
Gulseth, Michael .
ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) :1478-1487
[18]   Andexanet Alfa: First Global Approval [J].
Heo, Young-A .
DRUGS, 2018, 78 (10) :1049-1055
[19]   Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy [J].
Higashi, MK ;
Veenstra, DL ;
Kondo, LML ;
Wittkowsky, AK ;
Srinouanprachanh, SL ;
Farin, FM ;
Rettie, AE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (13) :1690-1698
[20]  
Hogg K, 2018, GOODMAN GILMANS PHAR